Open AccessSwitching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment‐experienced patients (pts) with HIV RNA <50 copies/mL
Author(s) -
Casado JL,
Domingo P,
Rubio R,
Antela A,
LopezRuz MA,
Castro A,
Portilla J,
Ribera E,
Podzamczer D,
Oteo JA,
Galindo J,
Otero S,
Lozano F,
Estrada V,
Moltó J,
Moreno S
Publication year - 2010
Publication title -
journal of the international aids society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.724
H-Index - 62
ISSN - 1758-2652
DOI - 10.1186/1758-2652-13-s4-p49
Subject(s) - medicine , tolerability , ritonavir , discontinuation , randomized controlled trial , gastroenterology , viral load , human immunodeficiency virus (hiv) , virology , adverse effect , antiretroviral therapy
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK